Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 2, 2007, Pages 900-906

  Pan, Clark Q ^a   Li, Fugang ^a   Tom, Irene ^a   Wang, Wei ^a   Dumas, Michael ^a   Froland, Wayne ^a   Yung, Stephanie L ^a   Li, Yaxin ^a   Roczniak, Steve ^a   Claus, Thomas H ^a   Wang, Y John ^a   Whelan, James P ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE DERIVATIVE; BAY 55 9837; GLUTAMINE DERIVATIVE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEAMINATION; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG STABILITY; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33846446037     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.112276     Document Type: Article

References (23)

1. Arulmozhi DK and Portha B (2006) GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 28:96-108.
2. Filipsson K, Pacini G, Scheurink AJ, and Ahren B (1998a) PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am J Physiol 274:E834-E842.
3. Filipsson K, Sundler F, Hannibal J, and Ahren B (1998b) PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regul Pept 74:167-175.
4. Filipsson K, Tornoe K, Holst J, and Ahren B (1997) Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J Clin Endocrinol Metab 82:3093-3098.
5. Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee HW, and Eiden LE (2002) Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci USA 99:461-466.
6. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
7. Harris JM, Martin NE, and Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
8. Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, and Jensen RT (2002) Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors. J Pharmacol Exp Ther 303:445-460.
9. Laburthe M, and Couvineau A (2002) Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regulatory Peptides 108:165.
10. Mody R, Tramontano A, and Paul S (1994) Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Int J Pept Protein Res 44:441-447.
11. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, and Laburthe M (2000) Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist: alanine scanning and molecular modeling of the peptide. J Biol Chem 275:24003-24012.
12. O'Donnell M, Garippa RJ, O'Neill NC, Bolin DR, and Cottrell JM (1991) Structure-activity studies of vasoactive intestinal polypeptide. J Biol Chem 266:6389-6392.
13. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, Macdougall M, Bell A, Claus TH, Clairmont KB, et al. (2006) Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem 281:12506-12515.
14. Pozo D (2003) VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 9:211-217.
15. Riddle MC and Drucker DJ (2006) Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29:435-449.
16. Sekiguchi Y, Kasai K, Hasegawa K, Suzuki Y, and Shimoda S (1994) Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro. Life Sci 55:1219-1228.
17. Sherwood NM, Krueckl SL, and McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619-670.
18. Theriault Y, Boulanger Y, and St-Pierre S (1991) Structural determination of the vasoactive intestinal peptide by two-dimensional H-NMR spectroscopy. Biopolymers 31:459-464.
19. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, et al. (2002) A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51:1453-1460.
20. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, and Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.
21. Wei Y and Mojsov S (1996) Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann NY Acad Sci 805:624-627.
22. Yokota C, Kawai K, Ohashi S, Watanabe Y, and Yamashita K (1995) PACAP stimulates glucose output from the perfused rat liver. Peptides 16:55-60.
23. Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M, Roczniak S, Todd T, Lemoine L, et al. (2003) Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem 278:10273-10281.